West Pharmaceutical Services (WST) Net Margin (2009 - 2026)

West Pharmaceutical Services has disclosed Net Margin across 18 years of filings, most recently posting 16.96% for Q2 2026.

• In Q2 2026, Net Margin rose 41.0% year-over-year to 16.96%; the TTM figure through Jun 2026 stood at 16.51% (up 52.0% YoY), while the FY2025 annual figure was 15.59%, down 93.0% from the prior year.
• Net Margin came in at 16.96% for Q2 2026 at West Pharmaceutical Services, up from 16.03% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 23.73% in Q2 2022 to a low of 12.38% in Q1 2025.
• Average Net Margin over 5 years is 17.6%, with a median of 17.03% recorded in 2024.
• Year-over-year, Net Margin tumbled 708 bps in 2022 and soared 423 bps in 2023.
• Over 5 years, Net Margin stood at 14.08% in 2022, then increased by 30 bps to 18.27% in 2023, then dropped by 6 bps to 17.11% in 2024, then decreased by 7 bps to 15.93% in 2025, then grew by 6 bps to 16.96% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 16.96% in Q2 2026, 16.03% in Q1 2026, and 15.93% in Q4 2025.